{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval was not reached at the time of data analysis.","groupId":"OG000","lowerLimit":"7.1","upperLimit":"NA","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Time measured from initiation of treatment till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 95% confidence interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"This outcome measure is assessed from patients enrolled onto Part A of this study.","id":"OG000","title":"Part A: Nivolumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initiation of treatment until death, assessed up to 2 years","title":"Overall Survival (Part A)","type":"SECONDARY","unitOfMeasure":"months"}